	US 12,138,266 B2
	Folate preparations
Martin Ulmann, Dachsen (CH); Gerd Wiesler, Lohn (CH); and Hans Dutler, Zürich (CH)
Assigned to Aprofol AG, (CH)
Appl. No. 17/256,456
Filed by APROFOL AG, Appenzell Steinegg (CH)
PCT Filed Jul. 1, 2019, PCT No. PCT/EP2019/067644 § 371(c)(1), (2) Date Dec. 28, 2020, PCT Pub. No. WO2020/002714, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 18181019 (EP), filed on Jun. 29, 2018.
Prior Publication US 2021/0267982 A1, Sep. 2, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61P 17/00 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0014 (2013.01); A61P 17/00 (2018.01)]

19 Claims

1. A method of treating epithelial tissue irritations and disorders, comprising topically administering a preparation comprising at least one folate salt to a patient in need thereof, wherein the folate salt comprises an anion selected from the group consisting of 5-formyl-(6RS)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl-(6RS)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5-methyl-10-formyl-(6S)-tetrahydrofolic acid, and 5,10-diformyl-(6S)-tetrahydrofolic acid.